Oric Pharmaceuticals Inc
NASDAQ:ORIC
Oric Pharmaceuticals Inc
NASDAQ:ORIC
Price:
9.21 USD
-5.15%
Updated:
May 6, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of ORIC.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ORIC
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
ORIC Competitors Multiples
Oric Pharmaceuticals Inc Competitors
Oric Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Oric Pharmaceuticals Inc
NASDAQ:ORIC
|
659.3m USD | 0 | -6.2 | -4.1 | -4.1 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
284.5B USD | 5.2 | 59 | 12.8 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
160B USD | 5.7 | 23.8 | 17.3 | 26 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
104.2B USD | 7.9 | 26.4 | 17.7 | 19.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.7B USD | 10.5 | 28.7 | 22.9 | 24 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133.1B AUD | 6.2 | 35.6 | 21.6 | 26.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.7B USD | 2.9 | 166.5 | 6.7 | 8.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
45.9B USD | 6.7 | -9.7 | -10.5 | -8.9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.9B USD | 3.3 | 27.3 | 14 | 17.5 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
